| Literature DB >> 21697994 |
Carole Drexel1, Anne Jacobson, Nicola A Hanania, Ben Whitfield, Jay Katz, Thomas Sullivan.
Abstract
BACKGROUND: Major clinical gaps impede the evidence-based treatment of chronic obstructive pulmonary disease (COPD) in the primary care setting. Studies are needed to measure the effectiveness of continuing medical education (CME) on improving physician competency and performance toward evidence-based COPD care.Entities:
Keywords: COPD; case vignettes; continuing medical education; effect size; outcomes measurement; practice patterns
Mesh:
Year: 2011 PMID: 21697994 PMCID: PMC3119105 DOI: 10.2147/COPD.S18257
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Effectiveness of educational intervention: measurement indicators
| Pathophysiology and natural history | In COPD, the ongoing inflammatory process leads to enlargement of the alveolar spaces, fibrosis, and destruction of the lung parenchyma; these changes increase with disease severity and persist on smoking cessation Cumulative exposure to noxious particles (including cigarette smoke) is the key risk factor for COPD Compared with men having COPD, women with COPD have greater susceptibility to toxic effects of smoking. |
| Diagnosis and staging | A diagnosis of COPD should be considered in any patient who has cough, sputum production, dyspnea, and/or a history of exposure to risk factors; the diagnosis is confirmed by spirometry A consensus statement by the National Lung Health Education Program recommends the widespread use of office spirometry by primary care providers for patients ≥45 years old who smoke cigarettes A good test requires a good effort on the part of the patient and enthusiastic coaching by the technician; for spirometry to be of value, the FVC test must be performed correctly Staging requires knowing FEV1 and FVC and understanding how to use them to stage a patient Patients with FEV1 <40% have severe COPD. |
| Treatment | Current pharmacotherapies do not change the natural history of COPD COPD needs to be treated early, and regular treatment with long-acting bronchodilators is an effective and convenient maintenance treatment For patients with severe COPD who have repeated exacerbations, glucocorticosteroids should be added to the treatment regimen Patients may be on a short-acting bronchodilator, a long-acting bronchodilator, a combination product, and glucocorticosteroids Unintentional nonadherence may reflect poor comprehension of the treatment regimen Nicotine dependence might function as a barrier to smoking cessation; nicotine dependence, in particular withdrawal, was related to a high number of quit attempts and to remaining a current smoker A number of Phase III clinical trials have assessed the potential utility of PDE4 inhibitors in the treatment of COPD. |
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; PDE4, phosphodiesterase 4.
Baseline demographics of effectiveness subgroup
| Patients seen per week with COPD | 11 | 15 |
| Years in practice | 28 years | 24 years |
| Specialty | ||
| Family practice | 50% | 52% |
| Internal medicine | 50% | 48% |
| Degree | ||
| MD/DO | 100% | 100% |
| Present employment | ||
| Solo practice | 45% | 38% |
| Group practice | 31% | 58% |
| Medical school | 0% | 2% |
| Health-management organization | 0% | 2% |
| Government | 25% | 0% |
| Practice location | ||
| Urban | 40.4% | 30.0% |
| Suburban | 55.3% | 52.0% |
| Rural | 4.3% | 18.0% |
Abbreviation: COPD, chronic obstructive pulmonary disease.
Case 1 survey results
| Based on the patient’s presentation, what is the most likely etiology for her shortness of breath? | |||||
| Alveolar destruction | 46 | 93.9% | 37 | 74.0% | 0.007 |
| Muscular deconditioning | 2 | 4.1% | 8 | 16.0% | |
| Synovial inflammation | 1 | 2.0% | 3 | 6.0% | |
| Increased left ventricular filling pressure | 0 | 0.0% | 2 | 4.0% | |
| Total respondents | 49 | 100.0% | 50 | 100.0% | |
| What is the most appropriate next step to diagnose her dyspnea? | |||||
| Repeat thyroid-stimulating hormone test | 1 | 2.0% | 1 | 2.0% | |
| Spirometry | 48 | 98.0% | 45 | 90.0% | 0.204 |
| Refer for cardiac catheterization | 0 | 0.0% | 2 | 4.0% | |
| Watchful waiting | 0 | 0.0% | 2 | 4.0% | |
| Total respondents | 49 | 100.0% | 50 | 100.0% | |
| What intervention would you recommend to improve her current condition? | |||||
| Advise that she take a daily aspirin | 0 | 0.0% | 1 | 2.0% | |
| Advise that she take an iron supplement | 0 | 0.0% | 0 | 0.0% | |
| Advise that she get her husband to quit smoking | 46 | 92.0% | 41 | 82.0% | 0.137 |
| Refer her to physical therapy | 4 | 8.0% | 8 | 16.0% | |
| Total respondents | 50 | 100.0% | 50 | 100.0% | |
Notes:
An evidence-based answer. Not all respondents answered every question.
Case 3 survey results
| What would you recommend as the next therapeutic step to improve COPD control in this patient? | |||||
| Prescribe home oxygen therapy | 1 | 2.0% | 1 | 2.0% | |
| Add a short-acting inhaled anticholinergic agent (ipratropium) | 17 | 34.0% | 16 | 32.0% | |
| Add an inhaled glucocorticosteroid | 32 | 64.0% | 33 | 66.0% | 0.834 |
| Refer for surgical evaluation | 0 | 0.0% | 0 | 0.0% | |
| Total respondents | 50 | 100.0% | 50 | 100.0% | |
| Compared with men, women with COPD tend to have: | |||||
| Less airway hyperresponsiveness | 0 | 0.0% | 11 | 22.0% | |
| Better health-related quality of life | 0 | 0.0% | 3 | 6.0% | |
| Greater susceptibility to the toxic effects of smoking | 44 | 89.8% | 27 | 54.0% | <0.001 |
| Increased probability of diagnosis on initial presentation | 5 | 10.2% | 9 | 18.0% | |
| Total respondents | 49 | 100.0% | 50 | 100.0% | |
| Which medication classes have been shown to change the natural history of COPD? | |||||
| Corticosteroid | 11 | 35.5% | 20 | 42.6% | |
| Corticosteroid + bronchodilator | 8 | 25.8% | 11 | 23.4% | |
| Bronchodilator | 5 | 16.1% | 9 | 19.1% | |
| Antibiotic + corticosteroid | 0 | 0.0% | 1 | 2.1% | |
| Phosphodiesterase 4 inhibitor | 2 | 6.5% | 0 | 0.0% | |
| None | 5 | 16.1% | 6 | 12.8% | 0.746 |
| Total respondents | 31 | 100.0% | 47 | 100.0% | |
| For which of the following inflammatory molecular targets in COPD is there an agent in Phase III development? | |||||
| PPAR-γ | 8 | 20.0% | 10 | 20.8% | |
| PDE4 | 26 | 65.0% | 16 | 33.3% | 0.003 |
| TNF α | 4 | 10.0% | 7 | 14.6% | |
| IL-8 | 2 | 5.0% | 15 | 31.3% | |
| Total respondents | 40 | 100.0% | 48 | 100.0% | |
Notes:
An evidence-based answer. Not all respondents answered every question.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; IL, interleukin; PDE4, phosphodiesterase 4; PPAR, peroxisome proliferation activated receptor; TNF, tumor necrosis factor.
Figure 1Familiarity with spirometry interpretation. Participants and nonparticipants were asked to rate their level of familiarity with spirometry interpretation on a scale of 1 (least familiar) to 10 (most familiar). Responses were analyzed by mean ranking and by proportion of responses indicating that physicians were not at all familiar (1–3), somewhat familiar (4–7), or extremely familiar (8–10) with spirometry interpretation.
Case 2 survey results
| What would be your next step in the management of this patient? | |||||
| Prescribe a macrolide or cephalosporin antibiotic | 16 | 32.7% | 21 | 42.0% | |
| Initiate a 21-day tapered oral glucocorticoid regimen | 3 | 6.1% | 4 | 8.0% | |
| Initiate a long-acting beta2-agonist | 30 | 61.2% | 25 | 50.0% | 0.261 |
| Admit the patient to the hospital | 0 | 0.0% | 0 | 0.0% | |
| Total respondents | 49 | 100.0% | 50 | 100.0% | |
| Which of the following studies would you use in his long-term management? | |||||
| Chest x-ray | 4 | 8.0% | 8 | 16.0% | |
| High-resolution chest CT | 3 | 6.0% | 3 | 6.0% | |
| Spirometry | 43 | 86.0% | 38 | 76.0% | 0.202 |
| Sleep study | 0 | 0.0% | 1 | 2.0% | |
| Total respondents | 50 | 100.0% | 50 | 100.0% | |
| Which of the following strategies would be most likely to improve the patient’s adherence? | |||||
| Provide in clear detail the results of recent trials showing mortality trends and benefits of therapy | 19 | 38.8% | 16 | 32.0% | |
| Identify the patient’s preferences about different therapeutic choices | 8 | 16.3% | 19 | 38.0% | |
| Assess the patient’s comprehension of different treatment options | 14 | 28.6% | 10 | 20.0% | 0.320 |
| Refer the patient to pulmonary rehabilitation | 8 | 16.3% | 5 | 10.0% | |
| Total respondents | 49 | 100.0% | 50 | 100.0% | |
| Based on the GOLD criteria, what severity stage is this patient? | |||||
| GOLD stage 1 – mild | 3 | 6.0% | 4 | 8.0% | |
| GOLD stage 2 – moderate | 18 | 36.0% | 24 | 48.0% | |
| GOLD stage 3 – severe | 29 | 58.0% | 22 | 44.0% | 0.161 |
| GOLD stage 4 – very severe | 0 | 0.0% | 0 | 0.0% | |
| Total respondents | 50 | 100.0% | 50 | 100.0% | |
Notes:
An evidence-based answer. Not all respondents answered every question.
Abbreviations: CT, computed tomography; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Pulmonary Diseases.
Figure 2Barriers to the management of chronic obstructive pulmonary disease. Mean barrier severity score on a scale of 1 (lowest significance) to 10 (highest significance).